{"id":"W7116985745","doi":"10.1136/bmjno-2025-001313","title":"Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial","year":2025,"lang":"en","type":"article","venue":"BMJ Neurology Open","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"National Health and Medical Research Council; Teva Pharmaceutical Industries; Mitsubishi Tanabe Pharma Corporation; GlaxoSmithKline; Biogen; Sanofi","keywords":"Clinical trial; Multiple sclerosis; Spironolactone; Protocol (science); Administration (probate law)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00410569,0.0005474298,0.002200986,0.0002042768,0.0003385136,0.00008822037,0.0009156836,0.0002062576,0.00002531422],"category_scores_gemma":[0.003656729,0.0002696094,0.0004240205,0.0004377702,0.0007799558,0.0001229865,0.0006845923,0.0003848613,0.000001014182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001091134,"about_ca_system_score_gemma":0.0003521387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008301804,"about_ca_topic_score_gemma":0.002646966,"domain_scores_codex":[0.993064,0.002655673,0.001882887,0.001066286,0.0006463996,0.0006847222],"domain_scores_gemma":[0.9924124,0.005006963,0.0007806291,0.001326728,0.0003121861,0.0001610789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8879074,0.05288778,0.04054449,0.0002473326,0.0007102126,0.00001604701,0.00500104,0.00006763163,0.0002378598,0.000004022029,0.00007728198,0.01229894],"study_design_scores_gemma":[0.8976764,0.03045111,0.06515014,0.0001821919,0.0003691691,0.000002038126,0.001982686,0.00187832,0.001077508,0.000001646631,0.001047306,0.000181448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.4996899,0.0000355795,0.00002409486,0.002275776,0.00008908667,0.4978056,0.00003621612,0.00001286334,0.00003088733],"genre_scores_gemma":[0.4386634,0.00001449217,0.0007369521,0.00009831452,0.00008446722,0.5602454,0.000005146208,0.00002131424,0.0001305677],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.06243976,"threshold_uncertainty_score":0.9999756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2817327530458859,"score_gpt":0.5059866021101453,"score_spread":0.2242538490642594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}